Quick Takeaways
- This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 03 Nov 2023, 16:15.
PATRICK DEVAL L - 01 Nov 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.
- Role
- Director
- Signature
- /s/ Mark Bodenrader, as Attorney-in-Fact
- Issuer symbol
- N/A
- Transactions as of
- 01 Nov 2023
- Net transactions value
- -$373,009
- Form type
- 4
- Filing time
- 03 Nov 2023, 16:15:10 UTC
- Previous filing
- 19 Sep 2023
- Next filing
- 19 Dec 2023
- SEC
- View on sec.gov
Quoteable Key Fact
"PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 03 Nov 2023."
What Changed
- Previous filing in this sequence was filed on 19 Sep 2023.
- Current net transaction value: -$373,009.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
CERE
transaction
Common Stock
Options Exercise
- Transaction value
- $380,241
- Shares
- +30,130
- Change %
- +918%
- Price
- $12.62
- Shares after
- 33,412
- Date
- 01 Nov 2023
- Ownership
- Direct
- Footnotes
- F1, F2
CERE
transaction
Common Stock
Sale
- Transaction value
- $753,250
- Shares
- -30,130
- Change %
- -90%
- Price
- $25.00
- Shares after
- 3,282
- Date
- 01 Nov 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
CERE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -30,130
- Change %
- -71%
- Price
- $0.000000
- Shares after
- 12,555
- Date
- 01 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,130
- Exercise price
- $12.62
- Footnotes
- F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. |
| F2 | Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan that were previously reported by the Reporting Person. |
| F3 | This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021. |